Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628431 | 0.89 | MAPK14 (0.50) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6609243 | 0.86 | MAPK14 (0.47) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6771571 | 0.85 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6614449 | 0.83 | MAPK14 (0.53) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6768218 | 0.82 | MAPK14 (0.53) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6779785 | 0.81 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6622348 | 0.81 | MAPK14 (0.50) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6623836 | 0.81 | MAPK14 (0.50) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6774189 | 0.80 | MAPK14 (0.50) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL6775549 | 0.78 | MAPK14 (0.49) | MAPK14CSNK1DMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383759-A1 | TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | The Procter & Gamble Company (US) | 2004-01-28 | — | — | EP | claimed |
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| WO-2002088108-A1 | TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-07 | — | — | WO | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885ALOX5 231/4885CSNK1D 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.